The reality is that if the biosimilar opportunity fails to deliver the return on investment once projected, the impact will be felt far less on the balance sheets of Big Pharma companies, many of which will continue to derive considerable revenue streams from branded biologic products.
FORBES: Gamekeeper or Poacher? - Big Pharma's Stance on Biosimilars